MAP kinases and the inflammatory signaling cascade as targets for the treatment of endometriosis?

Pietro Santulli, Santulli P, Piétro Santulli, Louis Marcellin, Marcellin L, Claudia Tosti, Chouzenoux S, Sandrine Chouzenoux, Cerles O, Olivier Cerles, Bruno Borghese, Frédéric Batteux, Charles Chapron, Chapron C
Expert opinion on therapeutic targets · 2015 · vol. 19(11) , pp. 1465–1483 · doi:10.1517/14728222.2015.1090974 · PMID:26389657 · W1720790551
review OA: closed CC0 ⤵ 55 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This review explores the role of MAP kinases in endometriosis-related inflammation and discusses the potential of MAPK inhibitors as non-contraceptive treatments for the disease.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

INTRODUCTION: The pathogenesis of endometriosis, a common benign disease, remains ill-defined, although it is clear that chronic inflammation plays a crucial role through mitogen-activated protein kinase (MAPK) signaling pathways. All current medical therapies for endometriosis are antigonadotropic, and therefore have a contraceptive effect. A concerted research effort is hence warranted with the aim of delivering novel therapeutics that reduces disease symptoms without blocking ovulation. AREAS COVERED: The authors review the complex pathogenic mechanisms of chronic inflammation in endometriosis and their relationships with MAPK pathways. The authors conducted a literature search of descriptive and functional targeted validation of MAPK in the pathogenesis of endometriosis. The effects of MAPK inhibitors, which constitute potential agents for future treatments, are also described. EXPERT OPINION: Preliminary studies have highlighted a crucial role for MAPK in driving endometriosis-related inflammation. MAPK inhibitors exhibit potent activity in terms of controlling growth of endometriosis lesions both in vitro and in animal models. As MAPK inhibitors are known to have a multitude of undesirable side effects, their use in humans has to be approached with great care. Indeed, use of these drugs would probably be limited to short exposures prior to surgery in cases involving the most severe disease phenotypes.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Inflammation Mitogen-Activated Protein Kinases Animals Drug Design Endometriosis Endometriosis Female Humans Inflammation Inflammation MAP Kinase Signaling System MAP Kinase Signaling System Mitogen-Activated Protein Kinases Mitogen-Activated Protein Kinases Protein Kinase Inhibitors Protein Kinase Inhibitors Protein Kinase Inhibitors Protein Kinase Inhibitors Signal Transduction

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (100)

Cited by (50)

Source provenance

europepmc
last seen: 2026-09-02T07:05:44.937405+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:17:39.907309+00:00
License: CC0 · commercial use OK